PRAME is a potential candidate for cancer immunotherapy because it is expressed by a variety of tumours and can induce T-cell immune responses.3, 5–8 In a phase I study, a combined plasmid-peptide vaccine derived from PRAME and prostate-specific membrane antigen was administered to patients with metastatic solid tumours who had failed standard treatment options.9 Expansion of PRAME-specific T-cells was observed and no safety issues were identified. The gene discussed is PRAME; the disease is neoplasm.